Natural Immunity and Covid-19: Twenty-Nine Scientific Studies to Share with Employers, Health Officials, and Politicians
BROWNSTONE INSTITUTE | OCTOBER 10, 2021
From the beginning of the March 2020 lockdowns for the SARS-CoV-2 virus, the subject of natural immunity (also called post-infection immunity) has been neglected. Once the vaccination became widely available, what began with near silence at the beginning turned nearly into a complete blackout of the topic.
Even now, there is an absence of open discussion, presumably in the interests of promoting universal vaccination and required documentation of such vaccination as a condition of participating in public life and even the jobs marketplace. Still, the science exists. Many studies exist. Their authors deserve credit, recognition, and to have their voices heard.
These studies demonstrate what was and is already known: natural immunity for a SARS-type virus is robust, long-lasting, and broadly effective even in the case of mutations, generally more so than vaccines. In fact, a major contribution of 20th-century science has been to expand upon and further elucidate this principle that has been known since the ancient world. Every expert presumably knew this long before the current debates. The effort to pretend otherwise is a scientific scandal of the highest order, especially because the continued neglect of the topic is affecting the rights and freedoms of billions of people.
People who have contracted the virus and recovered deserve recognition. For that matter, people who prefer an exposure risk to the virus in order to gain robust immunity deserve the freedom to make that choice. The realization that natural immunity – which pertains now to perhaps half of the US population and billions around the world – is effective in providing protection should have a dramatic effect on vaccine mandates.
Individuals whose livelihoods and liberties are being deprecated and deleted need access to the scientific literature as it pertains to this virus. They should send a link to this page far and wide. The scientists have not been silent; they just haven’t received the public attention they deserve. The preparation of this list was assisted by links provided by Paul Elias Alexander and Rational Ground’s own cheat sheet on natural immunity, which also includes links to popular articles on the topic.
1. One-year sustained cellular and humoral immunities of COVID-19 convalescents, by Jie Zhang, Hao Lin, Beiwei Ye, Min Zhao, Jianbo Zhan, et al. Clinical Infectious Diseases, October 5, 2021. “SARS-CoV-2-specific IgG antibodies, and also NAb can persist among over 95% COVID-19 convalescents from 6 months to 12 months after disease onset. At least 19/71 (26%) of COVID-19 convalescents (double positive in ELISA and MCLIA) had detectable circulating IgM antibody against SARS-CoV-2 at 12m post-disease onset. Notably, the percentages of convalescents with positive SARS-CoV-2-specific T-cell responses (at least one of the SARS-CoV-2 antigen S1, S2, M and N protein) were 71/76 (93%) and 67/73 (92%) at 6m and 12m, respectively. Furthermore, both antibody and T-cell memory levels of the convalescents were positively associated with their disease severity.”
2. Comparing SARS-CoV-2 natural immunity to vaccine-induced immunity: reinfections versus breakthrough infections, by Sivan Gazit, Roei Shlezinger, Galit Perez, Roni Lotan, Asaf Peretz, Amir Ben-Tov, Dani Cohen, Khitam Muhsen, Gabriel Chodick, Tal Patalon. MedRxiv, August 25, 2021. “Our analysis demonstrates that SARS-CoV-2-naïve vaccinees had a 13.06-fold increased risk for breakthrough infection with the Delta variant compared to those previously infected, when the first event (infection or vaccination) occurred during January and February of 2021. The increased risk was significant for a symptomatic disease as well…. This analysis demonstrated that natural immunity affords longer lasting and stronger protection against infection, symptomatic disease and hospitalization due to the Delta variant of SARS-CoV-2, compared to the BNT162b2 two-dose vaccine-induced immunity.”
3. Shedding of Infectious SARS-CoV-2 Despite Vaccination, by Kasen K. Riemersma, Brittany E. Grogan, Amanda Kita-Yarbro, Gunnar E. Jeppson, David H. O’Connor, Thomas C. Friedrich, Katarina M. Grande, MedRxiv, August 24, 2021. “The SARS-CoV-2 Delta variant might cause high viral loads, is highly transmissible, and contains mutations that confer partial immune escape. Outbreak investigations suggest that vaccinated persons can spread Delta. We compared RT-PCR cycle threshold (Ct) data from 699 swab specimens collected in Wisconsin 29 June through 31 July 2021 and tested with a qualitative assay by a single contract laboratory. Specimens came from residents of 36 counties, most in southern and southeastern Wisconsin, and 81% of cases were not associated with an outbreak. During this time, estimated prevalence of Delta variants in Wisconsin increased from 69% to over 95%. Vaccination status was determined via self-reporting and state immunization records.”
4. Necessity of COVID-19 vaccination in previously infected individuals, by Nabin K. Shrestha, Patrick C. Burke, Amy S. Nowacki, Paul Terpeluk, Steven M. Gordon, MedRxiv, June 5, 2021. “Individuals who have had SARS-CoV-2 infection are unlikely to benefit from COVID-19 vaccination, and vaccines can be safely prioritized to those who have not been infected before.”
5. Large-scale study of antibody titer decay following BNT162b2 mRNA vaccine or SARS-CoV-2 infection, by Ariel Israel, Yotam Shenhar, Ilan Green, Eugene Merzon, Avivit Golan-Cohen, Alejandro A Schäffer, Eytan Ruppin, Shlomo Vinker, Eli Magen. MedRxiv, August 22, 2021. “This study demonstrates individuals who received the Pfizer-BioNTech mRNA vaccine have different kinetics of antibody levels compared to patients who had been infected with the SARS-CoV-2 virus, with higher initial levels but a much faster exponential decrease in the first group.”
6. Discrete Immune Response Signature to SARS-CoV-2 mRNA Vaccination Versus Infection, by Ellie Ivanova, Joseph Devlin, et al. Cell, May 2021. “While both infection and vaccination induced robust innate and adaptive immune responses, our analysis revealed significant qualitative differences between the two types of immune challenges. In COVID-19 patients, immune responses were characterized by a highly augmented interferon response which was largely absent in vaccine recipients.”
7. SARS-CoV-2 infection induces long-lived bone marrow plasma cells in humans, by Jackson S. Turner, Wooseob Kim, Elizaveta Kalaidina, Charles W. Goss, Adriana M. Rauseo, Aaron J. Schmitz, Lena Hansen, Alem Haile, Michael K. Klebert, Iskra Pusic, Jane A. O’Halloran, Rachel M. Presti, Ali H. Ellebedy. Nature, May 24, 2021. “This study sought to determine whether infection with SARS-CoV-2 induces antigen-specific long-lived BMPCs in humans. We detected SARS-CoV-2 S-specific BMPCs in bone marrow aspirates from 15 out of 19 convalescent individuals, and in none from the 11 control participants…. Overall, our results are consistent with SARS-CoV-2 infection eliciting a canonical T-cell-dependent B cell response, in which an early transient burst of extrafollicular plasmablasts generates a wave of serum antibodies that decline relatively quickly. This is followed by more stably maintained levels of serum antibodies that are supported by long-lived BMPCs.”
8. Longitudinal analysis shows durable and broad immune memory after SARS-CoV-2 infection with persisting antibody responses and memory B and T cells, by Kristen W. Cohen, Susanne L. Linderman, Zoe Moodie, Julie Czartoski, Lilin Lai, Grace Mantus, Carson Norwood, Lindsay E. Nyhoff, Venkata Viswanadh Edara, et al. MedRxiv, April 27, 2021. “Ending the COVID-19 pandemic will require long-lived immunity to SARS-CoV-2. We evaluated 254 COVID-19 patients longitudinally from early infection and for eight months thereafter and found a predominant broad-based immune memory response. SARS-CoV-2 spike binding and neutralizing antibodies exhibited a bi-phasic decay with an extended half-life of >200 days suggesting the generation of longer-lived plasma cells. In addition, there was a sustained IgG+ memory B cell response, which bodes well for a rapid antibody response upon virus re-exposure.”
9. Incidence of Severe Acute Respiratory Syndrome Coronavirus-2 infection among previously infected or vaccinated employees, by N Kojima, A Roshani, M Brobeck, A Baca, JD Klausner. MedRxiv, July 8, 2021. “Previous SARS-CoV-2 infection and vaccination for SARS-CoV-2 were associated with decreased risk for infection or re-infection with SARS-CoV-2 in a routinely screened workforce. The was no difference in the infection incidence between vaccinated individuals and individuals with previous infection. Further research is needed to determine whether our results are consistent with the emergence of new SARS-CoV-2 variants.”
10. Single cell profiling of T and B cell repertoires following SARS-CoV-2 mRNA vaccine, by Suhas Sureshchandra, Sloan A. Lewis, Brianna Doratt, Allen Jankeel, Izabela Ibraim, Ilhem Messaoudi. BioRxiv, July 15, 2021. “Interestingly, clonally expanded CD8 T cells were observed in every vaccinee, as observed following natural infection. TCR gene usage, however, was variable, reflecting the diversity of repertoires and MHC polymorphism in the human population. Natural infection induced expansion of larger CD8 T cell clones occupied distinct clusters, likely due to the recognition of a broader set of viral epitopes presented by the virus not seen in the mRNA vaccine. Our study highlights a coordinated adaptive immune response where early CD4 T cell responses facilitate the development of the B cell response and substantial expansion of effector CD8 T cells, together capable of contributing to future recall responses.”
11. mRNA vaccine-induced T cells respond identically to SARS-CoV-2 variants of concern but differ in longevity and homing properties depending on prior infection status, Jason Neidleman, Xiaoyu Luo, Matthew McGregor, Guorui Xie, Victoria Murray, Warner C. Greene, Sulggi A. Lee, Nadia R. Roan. BioRxiv, July 29, 2021. “In infection-naïve individuals, the second dose boosted the quantity and altered the phenotypic properties of SARS-CoV-2-specific T cells, while in convalescents the second dose changed neither. Spike-specific T cells from convalescent vaccinees differed strikingly from those of infection-naïve vaccinees, with phenotypic features suggesting superior long-term persistence and ability to home to the respiratory tract including the nasopharynx. These results provide reassurance that vaccine-elicited T cells respond robustly to emerging viral variants, confirm that convalescents may not need a second vaccine dose, and suggest that vaccinated convalescents may have more persistent nasopharynx-homing SARS-CoV-2-specific T cells compared to their infection-naïve counterparts.”
12. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Jennifer M. Dan, Jose Mateus, Yu Kato, Kathryn M. Hastie, et al., Science, January 6, 2021. “Understanding immune memory to SARS-CoV-2 is critical for improving diagnostics and vaccines, and for assessing the likely future course of the COVID-19 pandemic. We analyzed multiple compartments of circulating immune memory to SARS-CoV-2 in 254 samples from 188 COVID-19 cases, including 43 samples at ≥ 6 months post-infection. IgG to the Spike protein was relatively stable over 6+ months. Spike-specific memory B cells were more abundant at 6 months than at 1 month post symptom onset. SARS-CoV-2-specific CD4+ T cells and CD8+ T cells declined with a half-life of 3-5 months. By studying antibody, memory B cell, CD4+ T cell, and CD8+ T cell memory to SARS-CoV-2 in an integrated manner, we observed that each component of SARS-CoV-2 immune memory exhibited distinct kinetics.”
13. Persistence of neutralizing antibodies a year after SARS-CoV-2 infection, by Anu Haveri, Nina Ekström, Anna Solastie, Camilla Virta, Pamela Österlund, Elina Isosaari, Hanna Nohynek, Arto A. Palmu, Merit Melin. MedRxiv, July 16, 2021. “We assessed the persistence of serum antibodies following wild-type SARS-CoV-2 infection six and twelve months after diagnosis in 367 individuals of whom 13% had severe disease requiring hospitalization. We determined the SARS-CoV-2 spike (S-IgG) and nucleoprotein IgG concentrations and the proportion of subjects with neutralizing antibodies (NAb).”
14. Quantifying the risk of SARS‐CoV‐2 reinfection over time, by Eamon O Murchu, Paula Byrne, Paul G. Carty, et al. Rev Med Virol. 2021. “Reinfection was an uncommon event (absolute rate 0%–1.1%), with no study reporting an increase in the risk of reinfection over time. Only one study esti- mated the population‐level risk of reinfection based on whole genome sequencing in a subset of patients; the estimated risk was low (0.1% [95% CI: 0.08–0.11%]) with no evidence of waning immunity for up to 7 months following primary infection. These data suggest that naturally acquired SARS‐CoV‐2 immunity does not wane for at least 10 months post‐infection. However, the applicability of these studies to new variants or to vaccine‐induced immunity remains uncertain.”
15. SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy, by Laith J. Abu-Raddad, Hiam Chemaitelly, Peter Coyle, Joel A. Malek. The Lancet, July 27, 2021. “Reinfection is rare in the young and international population of Qatar. Natural infection appears to elicit strong protection against reinfection with an efficacy ~95% for at least seven months.”
16. Natural immunity against COVID-19 significantly reduces the risk of reinfection: findings from a cohort of sero-survey participants, by Bijaya Kumar Mishra, Debdutta Bhattacharya, Jaya Singh Kshatri, Sanghamitra Pati. MedRxiv, July 19, 2021. “These findings reinforce the strong plausibility that development of antibody following natural infection not only protects against re-infection by the virus to a great extent, but also safeguards against progression to severe COVID-19 disease.”
17. Protection of previous SARS-CoV-2 infection is similar to that of BNT162b2 vaccine protection: A three-month nationwide experience from Israel, by Yair Goldberg, Micha Mandel, Yonatan Woodbridge, Ronen Fluss, Ilya Novikov, Rami Yaari, Arnona Ziv, Laurence Freedman, Amit Huppert, et al.. MedRxiv, April 24, 2021. “Similarly, the overall estimated level of protection from prior SARS-CoV-2 infection for documented infection is 94·8% (CI:[94·4, 95·1]); hospitalization 94·1% (CI:[91·9, 95·7]); and severe illness 96·4% (CI:[92·5, 98·3]). Our results question the need to vaccinate previously-infected individuals.”
18. Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection, by Asgar Ansari, Rakesh Arya, Shilpa Sachan, Someshwar Nath Jha, Anurag Kalia, Anupam Lall, Alessandro Sette, et al. Front Immunol. March 11, 2021. “Using HLA class II predicted peptide megapools, we identified SARS-CoV-2 cross-reactive CD4+ T cells in around 66% of the unexposed individuals. Moreover, we found detectable immune memory in mild COVID-19 patients several months after recovery in the crucial arms of protective adaptive immunity; CD4+ T cells and B cells, with a minimal contribution from CD8+ T cells. Interestingly, the persistent immune memory in COVID-19 patients is predominantly targeted towards the Spike glycoprotein of the SARS-CoV-2. This study provides the evidence of both high magnitude pre-existing and persistent immune memory in Indian population.”
19. Live virus neutralisation testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2, by Claudia Gonzalez, Carla Saade, Antonin Bal, Martine Valette, et al, MedRxiv, May 11, 2021. “ No significant difference was observed between the 20B and 19A isolates for HCWs with mild COVID-19 and critical patients. However, a significant decrease in neutralisation ability was found for 20I/501Y.V1 in comparison with 19A isolate for critical patients and HCWs 6-months post infection. Concerning 20H/501Y.V2, all populations had a significant reduction in neutralising antibody titres in comparison with the 19A isolate. Interestingly, a significant difference in neutralisation capacity was observed for vaccinated HCWs between the two variants whereas it was not significant for the convalescent groups.”
20. Highly functional virus-specific cellular immune response in asymptomatic SARS-CoV-2 infection, by Nina Le Bert, Hannah E. Clapham, Anthony T. Tan, Wan Ni Chia, et al, Journal of Experimental Medicine, March 1, 2021. “Thus, asymptomatic SARS-CoV-2–infected individuals are not characterized by weak antiviral immunity; on the contrary, they mount a highly functional virus-specific cellular immune response.”
21. SARS-CoV-2-specific T cell memory is sustained in COVID-19 convalescent patients for 10 months with successful development of stem cell-like memory T cells, Jae Hyung Jung, Min-Seok Rha, Moa Sa, Hee Kyoung Choi, Ji Hoon Jeon, et al, Nature Communications, June 30, 2021. “In particular, we observe sustained polyfunctionality and proliferation capacity of SARS-CoV-2-specific T cells. Among SARS-CoV-2-specific CD4+ and CD8+ T cells detected by activation-induced markers, the proportion of stem cell-like memory T (TSCM) cells is increased, peaking at approximately 120 DPSO. Development of TSCM cells is confirmed by SARS-CoV-2-specific MHC-I multimer staining. Considering the self-renewal capacity and multipotency of TSCM cells, our data suggest that SARS-CoV-2-specific T cells are long-lasting after recovery from COVID-19, thus support the feasibility of effective vaccination programs as a measure for COVID-19 control.”
22. Antibody Evolution after SARS-CoV-2 mRNA Vaccination, by Alice Cho, Frauke Muecksch, Dennis Schaefer-Babajew, Zijun Wang, et al, BioRxiv, et al, BioRxiv, July 29, 2021. “We conclude that memory antibodies selected over time by natural infection have greater potency and breadth than antibodies elicited by vaccination. These results suggest that boosting vaccinated individuals with currently available mRNA vaccines would produce a quantitative increase in plasma neutralizing activity but not the qualitative advantage against variants obtained by vaccinating convalescent individuals.” Newer version reads: “These results suggest that boosting vaccinated individuals with currently available mRNA vaccines will increase plasma neutralizing activity but may not produce antibodies with breadth equivalent to those obtained by vaccinating convalescent individuals.”
23. Differential effects of the second SARS-CoV-2 mRNA vaccine dose on T cell immunity in naïve and COVID-19 recovered individuals, by Carmen Camara, Daniel Lozano-Ojalvo, Eduardo Lopez-Granados. Et al., BioRxiv, March 27, 2021. “While a two-dose immunization regimen with the BNT162b2 vaccine has been demonstrated to provide a 95% efficacy in naïve individuals, the effects of the second vaccine dose in individuals who have previously recovered from natural SARS-CoV-2 infection has been questioned. Here we characterized SARS-CoV-2 spike-specific humoral and cellular immunity in naïve and previously infected individuals during full BNT162b2 vaccination. Our results demonstrate that the second dose increases both the humoral and cellular immunity in naïve individuals. On the contrary, the second BNT162b2 vaccine dose results in a reduction of cellular immunity in COVID-19 recovered individuals, which suggests that a second dose, according to the current standard regimen of vaccination, may be not necessary in individuals previously infected with SARS-CoV-2.”
24. COVID-19 natural immunity: Scientific Brief. World Health Organization. May 10, 2021. “Available scientific data suggests that in most people immune responses remain robust and protective against reinfection for at least 6-8 months after infection (the longest follow up with strong scientific evidence is currently approximately 8 months). Some variant SARS-CoV-2 viruses with key changes in the spike protein have a reduced susceptibility to neutralization by antibodies in the blood. While neutralizing antibodies mainly target the spike protein, cellular immunity elicited by natural infection also target other viral proteins, which tend to be more conserved across variants than the spike protein.”
25. SARS-CoV-2 re-infection risk in Austria, by Stefan Pilz, Ali Chakeri, John Pa Ioannidis, et al. Eur J Clin Invest. April 2021. “We recorded 40 tentative re-infections in 14 840 COVID-19 survivors of the first wave (0.27%) and 253 581 infections in 8 885 640 individuals of the remaining general population (2.85%) translating into an odds ratio (95% confidence interval) of 0.09 (0.07 to 0.13). We observed a relatively low re-infection rate of SARS-CoV-2 in Austria. Protection against SARS-CoV-2 after natural infection is comparable with the highest available estimates on vaccine efficacies. Further well-designed research on this issue is urgently needed for improving evidence-based decisions on public health measures and vaccination strategies.”
26. Anti-spike antibody response to natural SARS-CoV-2 infection in the general population, by Jia Wei, Philippa C. Matthews, Nicole Stoesser, et al, MedRxiv, July 5, 2021. “We estimated antibody levels associated with protection against reinfection likely last 1.5-2 years on average, with levels associated with protection from severe infection present for several years. These estimates could inform planning for vaccination booster strategies.”
27. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN), by Victoria Jane Hall, FFPH, Sarah Foulkes, MSc, Andre Charlett, PhD, Ana Atti, MSc, et al. The Lancet, April 29, 2021. “A previous history of SARS-CoV-2 infection was associated with an 84% lower risk of infection, with median protective effect observed 7 months following primary infection. This time period is the minimum probable effect because seroconversions were not included. This study shows that previous infection with SARS-CoV-2 induces effective immunity to future infections in most individuals.”
28. SARS-CoV-2 Natural Antibody Response Persists for at Least 12 Months in a Nationwide Study From the Faroe Islands, by Maria Skaalum Petersen, Cecilie Bo Hansen, Marnar Fríheim Kristiansen, et al, Open Forum Infectious Diseases, Volume 8, Issue 8, August 2021. “Although the protective role of antibodies is currently unknown, our results show that SARS-CoV-2 antibodies persisted at least 12 months after symptom onset and maybe even longer, indicating that COVID-19-convalescent individuals may be protected from reinfection. Our results represent SARS-CoV-2 antibody immunity in nationwide cohorts in a setting with few undetected cases, and we believe that our results add to the understanding of natural immunity and the expected durability of SARS-CoV-2 vaccine immune responses. Moreover, they can help with public health policy and ongoing strategies for vaccine delivery.
29. Associations of Vaccination and of Prior Infection With Positive PCR Test Results for SARS-CoV-2 in Airline Passengers Arriving in Qatar, by Roberto Bertollini, MD, MPH1; Hiam Chemaitelly, MSc2; Hadi M. Yassine. JAMA Research Letter, June 9, 2021. “Of 9180 individuals with no record of vaccination but with a record of prior infection at least 90 days before the PCR test (group 3), 7694 could be matched to individuals with no record of vaccination or prior infection (group 2), among whom PCR positivity was 1.01% (95% CI, 0.80%-1.26%) and 3.81% (95% CI, 3.39%-4.26%), respectively. The relative risk for PCR positivity was 0.22 (95% CI, 0.17-0.28) for vaccinated individuals and 0.26 (95% CI, 0.21-0.34) for individuals with prior infection compared with no record of vaccination or prior infection.”
Articles in the popular media
Why COVID-19 Vaccines Should Not Be Required for All Americans, by Marty Makary, US News, August 21, 2021
Having SARS-CoV-2 once confers much greater immunity than a vaccine—but vaccination remains vital, by Meredith Wadson, Science, August 26, 2021
Natural infection vs vaccination: Which gives more protection? By David Rosenberg, Israeli National News, July 13, 2021.
Flu survivors still immune after 90 years, by Ed Yong, National Geographic, August 17, 2008.
Rescind Vaccine Mandates: Open Letter to Medical Societies, Hospitals, Clinics, and Other Healthcare Facilities, Association of American Physicians and Surgeons, August 31, 2021.
University Vaccine Mandates Violate Medical Ethics, By Aaron Kheriaty and Gerard V. Bradley, Wall Street Journal, June 14, 2021.
Immunity to the Coronavirus May Last Years, New Data Hint, by Apoorva Mandavilli, New York Times, November 17, 2020.
COVID-19 induces lasting antibody protection, Tamari Bhandara, Washington University School of Medicine, May 24, 2021.
The World Health Organization Oversold the Vaccine and Deprecated Natural Immunity, by Jeffrey Tucker, Brownstone Institute, August 29, 2021.
Why Does the CDC Recognize Natural Immunity for Chicken Pox but Not Covid? By Paul Elias Alexander, Brownstone Institute, September 17, 2021.
Rand Paul and Xavier Becerra Square Off on Natural Immunity, with Devastating Results, by Brownstone Institute, October 2, 2021.
Lockdowns, Mandates, and Natural Immunity: Kulldorff vs. Offit, by Brownstone Institute, October 6, 2021.
Hospitals Should Hire, Not Fire, Nurses with Natural Immunity, by Martin Kulldorff, October 1, 2021.
The Strange Neglect of Natural Immunity, by Jayanta Bhattacharya, Brownstone Institute, July 28, 2021.
The Brownstone Institute for Social and Economic Research is a nonprofit organization conceived of in May 2021 in support of a society that minimizes the role of violence in public life.
Critics love Fauci’s new documentary, but audience hate it and accuse Rotten Tomatoes of ‘hiding’ low score

RT | October 11, 2021
Critics have almost universally praised the new documentary on Dr. Anthony Fauci, but audiences have seemingly hated it, even accusing review aggregator Rotten Tomatoes of trying to hide the movie’s unpopularity.
National Geographic’s ‘Fauci’ has been playing in select cinemas since September 10 and premiered on the Disney Plus streaming service last week. Trailers for the film focus heavily on Fauci and his work combating Covid-19, during which time he has become one of the more controversial figures in American politics.
The film, however, takes a positive look at Fauci and focuses more on tales about the health figure from his family, as well as public figures the infectious disease expert has worked with in the past, such as U2 frontman Bono and former President George W. Bush.
On Rotten Tomatoes, which aggregates reviews from selected critics and then gives a ‘rotten’ or ‘fresh’ score, the film holds a 91% positive rating, based on 30 positive reviews and three negative. The rating from audience members, however, was conspicuously missing from the website until Monday. As of Sunday, only one review, which was negative, had been posted despite the film being out for weeks.
The site was accused of ‘hiding’ the audience score in an effort to spin the movie’s increasingly negative coverage.
On Monday, an audience score did appear, and it showed valleys of difference in opinion from critics to the audience, with users awarding the film a 2% average from over 250 ratings (though it began with a 4% rating that has continually dropped). Despite the average now showing, there is still a lack of actual user reviews on the site, though many users may have chosen to simply drop a rating instead of writing a review.
“Two Americas,” writer Josh Jordan tweeted, including a screenshot of the ‘Tomatometer’ for ‘Fauci’ along with the recently-released comedy special from Dave Chappelle, which has been labeled transphobic by critics, but has been a popular title on Netflix. Critics on Rotten Tomatoes gave the movie a ‘rotten’ score of 33% while audiences awarded a near perfect score.
Fauci critics were quick to mock the film’s near-universal panning from audience members.
The Rotten Tomatoes score for ‘Fauci’ is just the tip of the iceberg when it comes to negative reviews. On IMDB, the movie has a 1.5 rating from over 6000 users.
Trailers for the movie on YouTube haven’t fared much better. One posted by National Geographic has over 100,000 ‘dislikes’ and less than 8000 ‘likes’, as of this writing.
A Disney Plus trailer, on the other hand, has just over 1000 ‘likes’ and over 20,000 ‘dislikes’.
Rotten Tomatoes has been accused of bias in the past, and the company has often chalked up near-universal negative reactions from audiences to trolls’ review-bombing.
In 2019, the company disabled pre-release comments and removed their ‘Want to See’ function – which allowed ratings based on how excited users were for a film – in response to early backlash against franchise pictures accused by critics of going ‘woke’, such as ‘Star Wars: The Last Jedi’ and ‘Captain Marvel’.
Two years before that decision, debate around Rotten Tomatoes and the political influence the audience can have was still a heated debate. Outspoken liberal and comedian Amy Schumer claimed in 2017 that her comedy special ‘The Leather Special’ was review-bombed by the “alt-right” over her comments on Donald Trump and other Republicans (50% critic rating/4% audience). At the time, the site responded again by limiting user functions by removing a five-star system in favor of a positive or negative rating from audiences.
On the opposite end of the spectrum, conservative artists have often pointed to the fact that films aimed at right-leaning audiences often score much lower with critics than audiences as proof the company is more open to ‘certifying’ liberal critics than right-of-center or conservative ones.
Producer John Aglialoro blamed near-universal bad reviews from “hateful” critics on Rotten Tomatoes for his 2011 film ‘Atlas Shrugged: Part I’ struggling to find an audience in theaters (he would go on to produce two sequels covering the last two thirds of Ayn Rand’s influential novel).
Trudeau Bans the Unvaccinated from Leaving the Country and from Earning a Living
The Justice Centre – October 7, 2021
CALGARY: The Justice Centre today responded to the federal government announcement that unvaccinated Canadians will lose their right to move and travel freely within Canada, their right to leave Canada, and their right to earn a living and participate in society without discrimination.
“The government is seeking to have 100% of Canadians injected with the experimental mRNA vaccine, which has not been subjected to any long-term testing on humans,” states lawyer John Carpay, President of the Justice Centre.
With the Canada-U.S. land border closed to non-essential travel, this Covid-19 vaccine travel mandate will effectively prevent unvaccinated people from leaving Canada in any way. In addition to denying unvaccinated Canadians the right to travel by plane or train, the federal government has also announced that federal employees and contractors will lose their jobs unless they participate in the world-wide experiment with new mRNA vaccines.
“We were recently promised, this past summer, that life would go back to normal once 70% of Canadians were injected with mRNA. This high vaccination rate has been achieved but has not stopped the spread of the virus. The new mRNA vaccine also provides no guarantee against the Delta variant,” continues Mr. Carpay.
According to media reports, Prime Minister Trudeau declared that these discriminatory measures against unvaccinated Canadians are needed to keep people “safe,” including children.
“Government data and statistics from every Canadian province, and from countries around the world, tell us that children, teenagers and young adults face no serious threat from Covid, which makes the Prime Minister’s rhetoric about saving children highly misleading,” continues Mr. Carpay.
“Medical reports and scientific studies make it clear that both vaccinated and unvaccinated people spread Covid-19. There is no scientific basis for turning unvaccinated Canadians into second-class citizens,” stated Allison Pejovic, Justice Centre Staff Lawyer.
Currently, Canada’s provincial and federal governments accept two injections as enough to qualify for “full” vaccination. But this may soon change to requiring three, four and more injections to maintain one’s legal status as “fully” vaccinated, as has been demonstrated in Israel and the Netherlands.
“Governments throughout history have used the notion of ‘science’ to support their policies, along with various appeals to public health, safety, security, morality, and so on. No government will violate human rights without putting forward a good-sounding justification, such as the war on terrorism, communism, online hate, drugs, or a nasty virus,” continues Mr. Carpay.
The government’s own data and statistics tell us that Covid is much closer to the annual flu than to the Spanish Flu of 1918. This matters because the entire world was put into a state of panic by the dire predictions of Dr. Neil Ferguson of Imperial College, who claimed in March of 2020 that Covid would be like the Spanish Flu of 1918, killing tens of millions of people.
“Canada’s vaccine passports, and the creation of first-class and second-class citizenship, are founded on Neil Ferguson’s demonstrably false claim that Covid is an unusually deadly killer,” states Mr. Carpay.
“Covid is real. Fear of Covid is wildly exaggerated. Over the past 18 months, government-funded media have been very successful in persuading the majority that vaccine passports (and lockdown policies preceding them) are based on science. When people hear a message thousands of times, they believe it to be true,” continues Mr. Carpay.
“The Justice Centre is profoundly disturbed that these federal mandates will prevent unvaccinated Canadians from leaving the country. Such a mandate is an egregious and unacceptable infringement of Canadians’ constitutionally protected mobility rights. There is no scientific justification for this,” concludes Ms. Pejovic.
These new government restrictions on civil liberties are still announcements at this stage, and no law has been passed by Parliament or by way of cabinet regulation (Order-in-Council). So, no legal challenge is possible at this time. If the government intends to implement these vaccine travel mandates and give them the force of law, these policies can then be challenged in court.
Doctor Says Physicians Are Being “Hunted” For Speaking Out by Press & Medical Boards
Dr Robert Malone branded a “terrorist” by Italian media

By Paul Joseph Watson | Summit News | October 7, 2021
Dr Robert Malone, the inventor of mRNA vaccines, says he was branded a “terrorist” by the media in Italy and warns that physicians who speak out are being “hunted via medical boards and the press.”
“I am going to speak bluntly,” tweeted Malone. “Physicians who speak out are being actively hunted via medical boards and the press. They are trying to deligitimize and pick us off one by one. This is not a conspiracy theory – this is a fact. Please wake up. This is happening globally.”
“I was labeled as a ‘terrorist’ in the Italian press when I was in Rome for the International COVID Summit. My crime? Advocating for early treatment of COVID-19 disease. I suggest that merits a bit of meditation,” he added.
Malone is one of many doctors who have been completely persecuted merely for discussing issues relating to COVID treatments and vaccine side-effects.
He has faced fierce opposition for his assertion that children shouldn’t be given COVID-19 vaccines and has also consistently highlighted concerns over links to myocarditis risk.
Those concerns are now being justified by Finland, Denmark and Sweden halting the Moderna jab for for younger males after reports of cardiovascular side effects.
Despite such concerns being regularly voiced by doctors, the Federation of State Medical Boards announced back in July that it would consider pulling medical licenses of doctors who traffic in “misinformation” about COVID.
In another stunning development, Malone’s IP address was blocked by the New England Journal of Medicine so he couldn’t read studies on their website.
The doctor said he was aware of how to get around the IP block, but called the move a “petty act.”
The War Against Ivermectin Intensifies
By Joel S. Hirschhorn | Principia Scientific | October 11, 2021
The unrelenting opposition to using ivermectin to treat and prevent COVID-19 is stronger than ever. This has resulted from a gigantic increase in demand for IVM by much of the public.
Despite big media tirades against IVM, the truth about its effectiveness (together with failure of COVID vaccines) has reached the public through many articles on alternative news websites and truth-tellers on countless podcasts. Its success has forced Big Pharma to create expensive copies of it.
And in my book Pandemic Blunder I made the case with data that using cheap, safe and effective generics like IVM and hydroxychloroquine would save 80 percent or more of COVID deaths. Esteemed physician Peter McCollough later said 85 percent. For the US, that means over 500,000 lives could have been saved, and globally over four million lives.
Meanwhile, hundreds of thousands of people worldwide have died from COVID vaccines, the failed solution to the pandemic.
Merck, a maker of IVM, is getting much positive press coverage for its forthcoming prescription oral antiviral (molnupiravir). It is designed to replace IVM that they cannot make big money from. FDA will soon give it emergency use authorization because of the emerging clarity that COVID vaccines do NOT work effectively or safely.
That the Washington Post says that what Merck has created is the “first covid-fighting pill” illustrates how awful big media has been in ignoring the proven benefits of the IVM and HCQ generics. And ignoring the many failures of COVID vaccines. In its October 2 front-page story on the new Merck pill, it did not even mention IVM or present any data showing IVM as proven even more effective than the new expensive drug tested on only hundreds of people for a short period.
In contrast, IVM has been used successfully on hundreds of thousands of people to treat and prevent COVID.
Speaking as someone who is using IVM as a prophylactic, here is what I have seen in recent times. Though getting a prescription for it is very difficult and stressful it can be done through a number of websites. But then the battle just begins. Many pharmacies, especially big chain ones, will not fill IVM prescriptions if there is any evidence that it is being used to fight COVID.
And then you will likely discover, as I did, that virtually no pharmacy (typically small community ones) that will fill such prescriptions has any IVM. That’s right. There is a national shortage of IVM because of huge demand in recent months and because US makers have not escalated production.
Probably, millions of vaccine resisters are using IVM, especially those resisting booster shots.
Can you still get it? Yes, and even without a prescription. It will have to come from India, with many makers of IVM. It can take many weeks to get it. But the cost is a tiny fraction of what US pharmacies have been charging when they did have it in stock. Rather than $4 or $5 for a 3 mg pill, you can buy 12 mg pills for way under $1 a pill.
But there is more to the IVM story.
There is absolutely no doubt whatsoever that there is massive medical science data showing absolute reliable data that IVM is safe and effective for both treating and preventing COVID. This is what should be a bold large headline in newspapers if we had honest big media: IVM SAFE AND EFFECTIVE ALTERNATIVE TO COVID VACCINES.
But instead, there is a constant barrage of articles and statements from government agencies asserting IVM should not be used to fight COVID. They argue it is unsafe and ineffective. Both are lies aimed solely at protecting the mass vaccination effort and the profits of big drug companies. And now protecting the new Big Pharma market for antiviral pills.
FDA has issued very strong warnings against using IVM for COVID. Nothing it has said follows the true science and mountains of data supporting safe and effective IVM use. Like other IVM opponents, it has conflated personal IVM use with the use of IVM products designed for animals.
This is even more infuriating. Merck, despite being a maker of IVM discredited its use for COVID by irresponsibly stating, “We do not believe that the data available support the safety and efficacy of ivermectin beyond the doses and populations indicated in the regulatory agency-approved prescribing information.”
Clearly, Merck, Pfizer and other vaccine makers are developing their own oral antivirals to directly compete with the cheap and effective IVM. These antivirals, unlike cheap generic IVM, would be patented so expensive pills could be sold worldwide. They will find some ingenious ways to copy IVM but make enough changes to get patents.
Already, Merck has begun production of its new pill to be taken twice daily for five days. Even more significant: The US government has made an advance purchase of 1.7 million treatment courses for $1.2 billion! That is over $700 per treatment. So much more profitable than making IVM. Forget the billions of dollars spent on vaccines that are injuring and killing many people.
I am confident in predicting that as more and more bad news about the ineffectiveness and dangerous side effects of COVID vaccines become increasingly known to more of the public, the big drug companies will increasingly switch from vaccines to prescription antiviral medicines.
This is what smart corporate business strategic planning is all about. With Merck, it has already started. And FDA, CDC and NIH will go along with this strategic switch.
This will preserve a trillion-dollar market for pharmaceutical companies. How the government and public health establishment weasel word their switch from COVID vaccines to antiviral pills will be a marvelous magical trick to watch. Do you think that they will admit that millions of people worldwide have lost their health and lives from vaccine use? Of course not. Expensive antiviral pills will simply be sold as a better solution.
Be clear about the science explaining why IVM and HCQ have worked. They both (along with zinc) interfere at the earliest stage of COVID infection with viral replication. Stop infection in its tracks. They work as prophylactics for the same reason.
If you keep a modest amount of IVM and HCQ in your body (and take zinc, vitamins C and D, and quercetin) any virus that enters your body can be stopped before major viral replication. The new prescription medicines coming from Merck and other Big Pharma are designed to serve the same function as the cheap generics.
This is the big truth coming to fruition: All the emerging information on COVID vaccine ineffectiveness and dangerous and often lethal side effects is forcing a major strategic shift to antivirals.
Congressman Louie Gohmert has recently made a number of solid observations about IVM:
“Almost 4 billion doses of ivermectin have been prescribed for humans, not horses, over the past 40 years. In fact, the CDC recommends all refugees coming to the U.S. from the Middle East, Asia, North Africa, Latin America, and the Caribbean receive this so-called dangerous horse medicine as a preemptive therapy.
Ivermectin is considered by the World Health Organization (WHO) to be an ‘essential medicine.’
The Department of Homeland Security’s ‘quick reference’ tool on COVID-19 mentioned how this life-saving drug reduced viral shedding duration in a clinical trial.”
“To date, there are at least 63 trials and 31 randomized controlled trials showing benefits to the use of ivermectin to fight COVID-19 prophylactically as well as for early and late-stage treatment. Ivermectin has been shown to inhibit the replication of many viruses, including SARS-CoV-2. It has strong anti-inflammatory properties and prevents transmission of COVID-19 when taken either before or after exposure to the virus.”
“Ivermectin also speeds up recovery and decreases hospitalization and mortality in COVID-19 patients. It has been FDA approved for decades and has very few and mild side effects. It has an average of 160 adverse events reported every year, which indicates ivermectin has a better safety record than several vitamins. In short, there is no humane, logical reason why it should not be widely used to fight against the China Virus should a patient and doctor decide it is appropriate to try in that patient’s case.”
And that small number of adverse events pales in comparison to hundreds of thousands for COVID vaccines.
A new, comprehensive report noted that 63 studies have confirmed the effectiveness of IVM in treating COVID-19. This is a great website to see positive IVM data.
And consider what former Director of Intellectual Property at Gilead Pharmaceuticals, Brian Remy, said about the necessity of implementing Ivermectin. “It is simple – use what works and is most effective – period. Ivermectin used in combination with other therapeutics is a no-brainer and should be the standard of care for COVID-19. Not only would this be good for business and help avoid the criticism and bad PR, and potential civil/criminal liability for censorship, scientific misconduct, etc. for misrepresentation of Ivermectin and other generics, but most importantly it would save countless lives and end the pandemic for good.” Amen.
Want even more positive facts? Consider the India experience. In India’s deadly second pandemic surge, Ivermectin obliterated their crisis. Within weeks after adopting IVM cases were down 90 percent. Those states with more aggressive IVM use were down more dramatically. Daily cases in Goa, Uttarakhand, Uttar Pradesh, and Delhi were down 95, 98, 99, and 99 percent, respectively.
And appreciate this: Dr. Kory and the FLCCC published a narrative review in May 2021, showing the massive effectiveness of IVM against COVID-19 in reducing death and cases. They concluded that it must be adopted globally immediately. Yet big media without respect for public health waged war against IVM. Now it is going crazy in support of the expensive Merck antiviral pill.
To sum up: The IVM story is far from over. We now have a pandemic of the vaccinated. From all over the world the fractions of people said to have died from COVID who were fully vaccinated are very high, often 80 percent. Many people with breakthrough COVID infections die.
Blame those deaths on the vaccines. Big media suppresses all the negative information on the vaccines and all the positive information on IVM.
This double whammy is pure evil. It is designed to pave the way for the new, expensive generation of antiviral pills once the medical and public health establishments backtrack from their vaccine advocacy and coercion.
About the author: Dr. Joel S. Hirschhorn, author of Pandemic Blunder and many articles on the pandemic, worked on health issues for decades. As a full professor at the University of Wisconsin, Madison, he directed a medical research program between the colleges of engineering and medicine. As a senior official at the Congressional Office of Technology Assessment and the National Governors Association, he directed major studies on health-related subjects; he testified at over 50 US Senate and House hearings and authored hundreds of articles and op-ed articles in major newspapers. He has served as an executive volunteer at a major hospital for more than 10 years. He is a member of the Association of American Physicians and Surgeons, and America’s Frontline Doctors.
Merck’s COVID ‘Super Drug’ Poses Serious Health Risks, Scientists Warn
“Proceed With Caution At Your Own Peril”
Tyler Durden | Zero Hedge | October 9, 2021
As it turns out, all the scientists and doctors who insisted that Merck’s “revolutionary” COVID drug molnupiravir is extremely safe weren’t faithfully adhering to “the science” after all. Because according to a report published Thursday by Barron’s, some scientists are worried that the drug – which purportedly cut hospitalizations in half during a study that was cut short – could cause cancer or birth defects.
So much for having a “strong safety profile,” as Dr. Scott Gottlieb claimed in an interview on the day Merck first publicized the research.
It’s perfectly understandable why Merck might choose to play down this safety risk: assuming it’s approved, the drug is widely expected to be one of “the most lucrative drugs ever” – which is one reason why Merck’s shares soared into double-digit territory after the announcement.
As we reported earlier this week, Merck and its “partner” Ridgeback Biotherapeutics will profit immensely by charging customers up to 40x what it costs to make the drug, which Ridgeback originally licensed from Emory University for an “undisclosed sum”. The drug was developed with funding from the federal government.
According to Barron’s, some scientists who have studied the drug believe that its method of suppressing the virus could potentially run amok within the body.
Some scientists who have studied the drug warn, however, that the method it uses to kill the virus that causes Covid-19 carries potential dangers that could limit the drug’s usefulness.
Molnupiravir works by incorporating itself into the genetic material of the virus, and then causing a huge number of mutations as the virus replicates, effectively killing it. In some lab tests, the drug has also shown the ability to integrate into the genetic material of mammalian cells, causing mutations as those cells replicate.
If that were to happen in the cells of a patient being treated with molnupiravir, it could theoretically lead to cancer or birth defects.
In particular, Raymond Schinazi, a professor of pediatrics and the director of biochemical pharmacology at Emory who studied the drug while it was being developed, and published a number of papers on NHC, the compound that’s the active ingredient in the drug. He published a paper that showed the drug can produce a reaction like the one described above, and insisted it shouldn’t be given to young people – especially pregnant women – without more data.
Schinazi told Barron’s that he did not believe that molnupiravir should be given to pregnant women, or to young people of reproductive age, until more data is available. Merck’s trials of molnupiravir have excluded pregnant women; the scientists running the trial asked male participants to “abstain from heterosexual intercourse” while taking the drug, according to the federal government website that tracks clinical trials.
Barron’s even shared a paper published in the Journal of Infectious Diseases in May by Schinazi and scientists at the University of North Carolina which reported that NHC can cause mutations in animal cell cultures in a lab test designed to detect such mutations – something Merck claims it has tested for. The paper’s authors concluded that the risks for molnupiravir “may not be zero”.
Merck told Barron’s that it has run “extensive tests” on animals which it says show that this shouldn’t be an issue. “The totality of the data from these studies indicates that molnupiravir is not mutagenic or genotoxic in in-vivo mammalian systems,” a Merck spokesman said.
Still, scientists and doctors who have studied NHC say that Merck needs to “be careful,” and it’s not just Schinazi warning about the drug’s potential risks.
Dr. Shuntai Zhou, a scientist at the Swanstrom Lab at UNC, said “there is a concern that this will cause long-term mutation effects, even cancer.”
Zhou says that he is certain that the drug will integrate itself into the DNA of mammalian hosts. “Biochemistry won’t lie,” he says. “This drug will be incorporated in the DNA.”
Merck hasn’t yet released any data from its animal studies, but the scientists believe that it would take long-term studies to show that the drug is truly totally safe.
“Proceed with caution and at your own peril,” wrote Raymond Schinazi, a professor of pediatrics and the director of the division of biochemical pharmacology at the Emory University School of Medicine, who has studied NHC for decades, in an email to Barron’s.
Analysts are already warning that these questions about the drug’s safety suggest the reaction in Merck’s shares was a little “overblown”, to say the least. Investors apparently were so eager for a new “pandemic panacea” (now that the mRNA jabs have proven to be much less effective than advertised) that they didn’t ask too many questions about safety, or even question the paucity of data. One analyst for SVB Leerink Dr. Geoffrey Porges described investors’ reaction from Friday as “wishful thinking”.
Even once the FDA authorizes the drug, Dr. Porges believes it will come with strict limitations on who can and can’t use it. “I think it is effectively going to be a controlled substance”, Dr. Porges said, adding that the risks to pregnant women, or women who may soon become pregnant, could present thorny problems for the FDA’s advisory committee reviewing the drug.
Given that the safety risks of the drug seem well-documented already, Wall Street’s gushing about the drug’s prospects – “it really is THAT good”, one analyst insisted – seems like an idiotic blunder in retrospect. The product of what one might call “magical thinking”.
Reports of Serious Injuries After COVID Vaccines Near 112,000, as Pfizer Asks FDA to Green Light Shots for Kids 5 to 11
By Megan Redshaw | The Defender | October 8, 2021
Data released Friday by the Centers for Disease Control and Prevention (CDC) showed that between Dec. 14, 2020 and Oct. 1, 2021, a total of 778,685 adverse events following COVID vaccines were reported to the Vaccine Adverse Event Reporting System (VAERS). The data included a total of 16,310 reports of deaths — an increase of 373 over the previous week.
There were 111,921 reports of serious injuries, including deaths, during the same time period — up 6,163 compared with the previous week.
Excluding “foreign reports” filed in VAERS, 593.728 adverse events, including 7,437 deaths and 47,455 serious injuries, were reported in the U.S. between Dec. 14, 2020 and Oct. 1, 2021.
Of the 7,437 U.S. deaths reported as of Oct. 1, 11% occurred within 24 hours of vaccination, 16% occurred within 48 hours of vaccination and 29% occurred in people who experienced an onset of symptoms within 48 hours of being vaccinated.
In the U.S., 393.4 million COVID vaccine doses had been administered as of Oct. 1. This includes: 227 million doses of Pfizer, 152 million doses of Moderna and 15 million doses of Johnson & Johnson (J&J).

The data come directly from reports submitted to VAERS, the primary government-funded system for reporting adverse vaccine reactions in the U.S.
Every Friday, VAERS makes public all vaccine injury reports received as of a specified date, usually about a week prior to the release date. Reports submitted to VAERS require further investigation before a causal relationship can be confirmed.
Historically, VAERS has been shown to report only 1% of actual vaccine adverse events.
This week’s U.S. data for 12- to 17-year-olds show:
- 21,298 total adverse events, including 1,284 rated as serious and 22 reported deaths. Two of the 22 deaths were suicides.
The most recent death involves a 16-year-old male (VAERS I.D. 1734141) who reportedly died from cardiac failure five days after receiving Pfizer’s COVID vaccine.
Other recent deaths include a 17-year-old male (VAERS I.D. 1689212) with cancer who was vaccinated April 17, tested positive for COVID on July 20, was hospitalized and passed away Aug. 29; and a 16-year-old female (VAERS I.D. 1694568) who died from a pulmonary embolism nine days after receiving her first Pfizer dose.
- 3,202 reports of anaphylaxis among 12- to 17-year-olds with 99% of cases
attributed to Pfizer’s vaccine. - 520 reports of myocarditis and pericarditis (heart inflammation) with 508 cases attributed to Pfizer’s vaccine.
- 114 reports of blood clotting disorders, with all cases attributed to Pfizer.
This week’s U.S. VAERS data, from Dec. 14, 2020 to Oct. 1, 2021, for all age groups combined, show:
- 19% of deaths were related to cardiac disorders.
- 56% of those who died were male, 43% were female and the remaining death reports did not include gender of the deceased.
- The average age of death was 72.8.
- Of the 2,935 cases of Bell’s Palsy reported, 50% were attributed to Pfizer vaccinations, 42% to Moderna and 8% to J&J.
- 648 reports of Guillain-Barré syndrome, with 40% of cases attributed to Pfizer, 32% to Moderna and 28% to J&J.
- 1,976 reports of anaphylaxis where the reaction was life-threatening, required treatment or resulted in death.
- 158,280 reports of symptoms of anaphylactic reactions with 43% of cases attributed to Pfizer’s vaccine, 49% to Moderna and 7% to J&J. An anaphylactic reaction may include various symptoms like skin rashes, nausea, vomiting, difficulty breathing or shock.
- 9,907 reports of blood clotting disorders. Of those, 4,286 reports were attributed to Pfizer, 3,595 reports to Moderna and 1,975 reports to J&J.
- 2,737 cases of myocarditis and pericarditis with 1,733 cases attributed to Pfizer, 888 cases to Moderna and 106 cases to J&J’s COVID vaccine.
Young mother pressured to receive COVID vaccine dies of vaccine-induced blood clots
Jessica Berg Wilson, a 37-year-old stay-at-home mother from Washington passed away suddenly on Sept. 7 from vaccine-induced thrombotic thrombocytopenia (VITT) — a rare, and sometimes fatal, blood-clotting condition — after receiving J&J’s COVID vaccine.
On Aug. 29, Jessica went to a Seattle pharmacy to get her COVID vaccine and was told she would be receiving J&J’s shot. She was “vehemently opposed” to taking the vaccine, “considering her stay-at-home mom status, state of good health and young age in conjunction with the known and unknown risk of an unproven vaccine,” her husband said.
But Jessica was pressured to get the vaccine due to a vaccine mandate at their child’s school requiring “room moms” who wished to serve in the classroom be fully vaccinated.
According to Jessica’s VAERS report (VAERS I.D. 1683324), she experienced blood clots in her ovarian and renal veins, and a brain hemorrhage that led to tissue damage. Although doctors tried to relieve the pressure on her brain by performing a craniotomy, they were unsuccessful.
Jessica was ultimately pronounced brain dead, removed from life support and passed away. Doctors confirmed the cause of death was VITT.
Pfizer asks FDA to authorize emergency use of its COVID vaccine for 5- to 11-year-olds
Pfizer and its German partner, BioNTech on Thursday asked the U.S. Food and Drug Administration (FDA) to authorize their COVID vaccine for emergency use for children 5 to 11 years old. The FDA advisory committee is scheduled to meet Oct. 26 to discuss Pfizer’s pediatric COVID vaccine.
FDA officials said once vaccine data for younger children was submitted, the agency could authorize a vaccine for younger children in a matter of weeks, but it would depend on the timing and quality of the data provided.
Pfizer and BioNTech submitted initial data to the FDA last month for a regimen of two 10-microgram doses in children — one-third the amount given to older patients — but had not formally requested authorization until now.
According to Pfizer’s Sept. 20 press release, the trial didn’t show the vaccine reduced hospitalizations or even mild cases. But it did reveal side effects generally comparable to those observed in participants 16 to 25 years of age.
Studies confirm Pfizer vaccine immunity wanes at 2 months
As The Defender reported, two studies published Wednesday in the New England Journal of Medicine confirm any immune protection offered by two doses of Pfizer’s COVID vaccine drops off after roughly two months.
A prospective longitudinal study from Israel covering 4,800 healthcare workers showed antibody levels waned rapidly after two doses of vaccine “especially among men, among persons 65 years of age or older and among persons with immunosuppression.”
A second study from Qatar looked at actual infections among the nation’s highly vaccinated population, who mostly received Pfizer’s COVID vaccine. Estimated effectiveness against SARS-CoV-2 infection was negligible for the first two weeks after the first Pfizer dose, increased to 36.8% in the third week after the first dose, and reached its peak at 77.5% in the first month after the second dose.
By months five five through seven, researchers said vaccine efficacy reached a low level of approximately 20%. Pfizer has consistently claimed the company’s own efficacy data demonstrate 95% efficacy against SARS-CoV-2, which was not observed in this study.
Sweden, Denmark and Finland pause Moderna vaccine over concerns of myocarditis
Sweden, Denmark and Finland will pause the use of Moderna’s COVID vaccine for younger age groups after reports of possible rare side effects, including myocarditis.
Finland on Thursday paused the use of Moderna’s COVID vaccine for younger males due to reports of myocarditis, joining Sweden and Denmark in limiting its use after a Nordic study involving Finland, Sweden, Norway and Denmark found men under the age of 30 who received Moderna’s vaccine had a slightly higher risk than others of developing myocarditis.
All four countries said they would instead give Pfizer’s vaccine to men born in 1991 and later, despite research that shows a similar risk of myocarditis associated with Pfizer’s vaccine.
Fully vaccinated patient sparks COVID outbreak among vaccinated population
A paper published Sept. 30, in Eurosurveillance showed a fully vaccinated patient in a hospital setting rapidly spread COVID to fully vaccinated staff, patients and family members — despite a 96% vaccination rate and use of full personal protective equipment.
Of the 42 cases diagnosed in the outbreak, 38 were fully vaccinated with two doses of Pfizer and BioNTech’s Comirnaty vaccine, one had received only one vaccination and three were unvaccinated.
Of the infected, 23 were patients and 19 were staff members. The staff all recovered quickly. However, eight vaccinated patients became severely ill, six became critically ill and five of the critically ill died. The two unvaccinated patients had mild COVID cases.
The authors said the study challenges the assumption high universal vaccination rates will lead to herd immunity and prevent COVID outbreaks, as 96.2% of the outbreak subjects were vaccinated, infection advanced rapidly and viral load was high.
Fully vaccinated countries had the highest number of new COVID cases
In a study published Sept. 30 in the peer-reviewed European Journal of Epidemiology Vaccines, researchers investigated the relationship between the percentage of population fully vaccinated and new COVID cases across 68 countries and 2,947 U.S. counties that had second dose vaccine, and available COVID case data.
The study found “no discernible relationship” between the percentage of population fully vaccinated and new COVID cases. In addition, the most fully vaccinated nations had the highest number of new COVID cases, based on the researchers’ analysis of emerging data during a seven-day period in September.
Children’s Health Defense asks anyone who has experienced an adverse reaction, to any vaccine, to file a report following these three steps.
Megan Redshaw is a freelance reporter for The Defender. She has a background in political science, a law degree and extensive training in natural health.
© 2021 Children’s Health Defense, Inc. This work is reproduced and distributed with the permission of Children’s Health Defense, Inc. Want to learn more from Children’s Health Defense? Sign up for free news and updates from Robert F. Kennedy, Jr. and the Children’s Health Defense. Your donation will help to support us in our efforts.
My suspicions about the flu jab and ‘Plan B’
By Lynne Collings | TCW Defending Freedom | October 9, 2021
WHY did I have my first flu jab? I think it might have been because I saw a sign in the surgery or was told about the sessions via the ‘Patient Participation Group’ who send out an e-newsletter a couple of times a year. My husband, as a mild asthmatic, had had the jab for several years but I found myself faintly reluctant to have one myself. I had no good reason other than something that I can’t put my finger on but which makes me stay away from surgeries and hospitals.
Or perhaps it was because I remember the flu jab sessions run by the surgery I worked in which were wonderfully happy and funny occasions where the elderly of the town lined up in the large waiting room, some sitting, some leaning on sticks but all with a sleeve rolled up expectantly. They were having an outing where they laughed and joked amongst themselves, especially when the doctor passed down the line with a massive syringe using the same needle which he inserted into each arm – yes, it was that long ago. After the session many were reluctant to leave. So how did having a flu jab change from something that was given to the elderly for what had always been assumed to be their own benefit into something you did so that you didn’t ‘kill your granny’, the very people whom the flu jab was supposed to benefit in the first place?
Hear what Dr Fauci said on September 28 on CNN: ‘Everyone who’s at least six months old should get a flu vaccine. Not only will getting a flu shot help protect you and those around you from potentially life-threatening flu complications, doing so will also keep the limited supply of hospital beds available for COVID-19 patients who need them right now.’
Telegraph headline yesterday: ‘Flu deaths could hit 60,000 in worst winter for 50 years, say experts’. The story says that more than 35million people will be offered flu jabs after warnings from health chiefs that lockdowns and social distancing have led to a drop in immunity. There is concern that the combination of Covid-19 and flu could cripple health services, increasing the risk of another lockdown, or ‘Plan B’ measures such as compulsory masks, vaccine passports or a return to working from home.
Did I really just read that ‘lockdowns and social distancing have led to a drop in immunity’? What can this mean? That they have finally come to their senses about the negative health effects of lockdown, so it will never be repeated? No, I don’t think so.
They are simply using this terrible truth to bolster, indeed double down on their next fear mongering project. Which is to tie us into a controlled system of repeat vaccination (whether for flu or Covid) as the price of our supposed freedom from more lockdown.
An advertising campaign will urge those eligible for the flu vaccine and Covid-19 booster jab to book their appointments as soon as possible.
Health Secretary Sajid Javid in the Telegraph article: ‘This year we are rolling out the largest flu vaccine programme in our history, alongside the new Covid-19 booster vaccine rollout; both are important to provide vital protection not only to yourself, but also your loved ones while also helping to ease pressure on the NHS.’
From the same article: ‘Earlier this week, Professor Neil Ferguson . . . said the UK did not have much “headroom” for rising Covid-19 cases before the NHS becomes “heavily stressed”.’
Earlier this year I signed up for the NHS app via my iPad because my surgery suggested it as an aid to the reorganisation that is being undertaken while we are out of the way. I had already the two Covid jabs as I understood they would help release everyone else, and there they were, dates and code numbers, popping up on the app. Aha, I thought, here is the Covid passport of the future.
Now if I look at the app it tells me that my first two jabs will no longer be relevant after November 7, and that I have my own QR code which will let me use a Domestic Covid Pass ‘at places that have chosen to use the service’. The dreaded Covid passport that I had foolishly thought to avoid by not travelling around with the app on my iPhone was there on my iPad which I use only at home. I have considered deleting the app but a warning is issued: ‘After you have deleted this app they might keep some information about you’. Who are ‘they’ and what on earth might they keep about me? I have an awful feeling it is likely to be the facial recognition process that I went through in order to sign up to this app.
Once you have the app the NHS prefers to contact you via text message, and I have been offered a flu jab. What will happen in future if I need treatment and it is found that I ‘declined’ the flu jab? I have declined at the moment but if I do decide to go ahead, as I have in the past, I will go to a pharmacy as it will be my decision which I hope to keep off the app. Is this being foolish? I really don’t know. All I know is it seems that the rolling out of Covid passports is where we are headed like it or not, together with the dreaded Plan B. Please tell me I am wrong. Why would Public Health England be renamed the UK Health Security Agency if the intentions were otherwise?
I believe the emergency powers are to be voted on in the House of Commons on October 19. Is all this leading up to an extension of these powers for another six months allowing Plan B to be implemented with as little as one week’s notice? Just see how many firework displays are now planned via Zoom. I believe local authorities have known of the likelihood of Plan B for some time, and what would give a big boost to ‘Health Security’? Why, the banning of dangerous firework displays.
‘Superspreader of misinformation’: NYT corrects story that exaggerated child Covid-19 hospitalizations by over 90%
RT | October 8, 2021
The New York Times had to issue a doozy of a correction on an article by its Covid-19 reporter Apoorva Mandavilli, who somehow inflated the number of US children hospitalized with the virus to 14 times the actual level.
Mandavilli claimed in her article, published on Tuesday, that nearly 900,000 Covid-infected children had been hospitalized in the US since the pandemic began. As the Times admitted on Thursday, the available data shows that the correct figure from August 2020 to October 2021 was more than 63,000.
The inaccuracies didn’t stop there. The correction also noted that contrary to Mandavilli’s reporting, Sweden and Denmark haven’t begun offering single-dose vaccines to children. The newspaper added that the story misstated the timing of an upcoming FDA meeting regarding proposed use of the Pfizer-BioNTech vaccine in children as young as five years old.
The scale of the erroneous hospitalization figure was reminiscent of gaffes by President Joe Biden, such as saying 120 million Americans had died from Covid-19 and 150 million had been killed by gun violence. It’s not clear how the blunder occurred, but the mainstream media has been accused of hyping the severity of the pandemic. A hidden-camera investigation by Project Veritas in April purported to show a CNN technical director saying the outlet purposely stoked fears of Covid-19 to boost ratings.
Ironically, the Times itself has decried Covid-19 misinformation. For instance, the newspaper posted an article earlier this week vilifying Dr. Joseph Mercola as “the most influential spreader of coronavirus misinformation.” In August, the Times said ‘Russian disinformation’ was being spread to suggest that the Biden administration would impose a Covid-19 vaccine mandate. A month later, Biden ordered that healthcare facilities, federal contractors and businesses with more than 100 employees force their workers to be inoculated, taking the choice over getting the jab away from about 100 million Americans.
While the Times and other mainstream outlets have billed themselves as the arbiters of truth, Mandavilli’s error-laced article is only the latest in a long line of inaccurate reporting by the newspaper. For example, the newspaper falsely claimed that Russia had offered bounties on American troops in Afghanistan and that police officer Brian Sicknick was murdered by pro-Trump rioters at the US Capitol.
“The New York Times is a superspreader of misinformation,” said Christina Pushaw, press secretary for Florida Governor Ron DeSantis.
Mandavilli stirred anger among conservatives in May, when she said the theory that Covid-19 leaked from China’s Wuhan Institute of Virology had “racist roots.” She later deleted her Twitter post, lamenting that the pushback to her remark had been “ridiculous.”
“Someday, we will stop talking about the lab-leak theory and maybe even admit its racist roots,” Mandavilli said in the original tweet. “But alas, that day is not yet here.”
It’s not clear why the reporter was rooting for the lab leak theory to go away, as even chief White House medical adviser Dr. Anthony Fauci said it should be investigated after previously trying to squash the notion.
The Wall Street Journal had reported two days earlier that three scientists at the Wuhan lab had been hospitalized with Covid-19 symptoms in the fall of 2019, near the time when the first cases of the virus were reported in China.
The Times’ former lead reporter on Covid-19, Pulitzer Prize nominee Donald McNeil Jr., resigned under pressure in February after co-workers campaigned for his firing. His sin was responding to a high school student’s question about a classmate’s use of the N-word by repeating the slur when he asked for context on how it was used. He had worked for the newspaper since 1976.


